Welcome to our dedicated page for VERTEX PHARMACEUTICALS / MA SEC filings (Ticker: VRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VERTEX PHARMACEUTICALS / MA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VERTEX PHARMACEUTICALS / MA's regulatory disclosures and financial reporting.
Vertex Pharmaceuticals executive Carmen Bozic reported an open-market sale of 1,974 shares of Common Stock at $450.00 per share. The transaction left her with 22,760 shares held directly. According to the disclosure, the sale was made under a pre-arranged Rule 10b5-1 trading plan entered into on 11/20/2025, indicating it was scheduled in advance rather than timed discretionarily.
Vertex Pharmaceuticals insider sale notice: A Form 144 submission lists proposed or recent dispositions of Common stock by Joy Liu. The excerpt shows three reported sales in the past three months: 03/02/2026 (892 shares, $442,396.32), 04/01/2026 (978 shares, $439,288.26), and 05/01/2026 (1,104 shares, $469,222.08). The filing also records an allocation of 828 shares tied to Restricted Stock Vesting dated 02/26/2025.
VRTX reported proposed sales and recent dispositions in a Form 144 submission. The filing lists two restricted stock vesting events (1,020 shares on 02/17/2026 and 954 shares on 02/24/2026) and four reported sales by Carmen R. Bozic between 03/13/2026 and 05/15/2026.
Vertex Pharmaceuticals executive Mark E. Bunnage reported a small open-market sale of company stock. On this Form 4, the EVP and Chief Scientific Officer sold 33 shares of Common Stock at $453.45 per share and now directly holds 7,284 shares. The transaction was made under a pre-arranged Rule 10b5-1 trading plan entered into on November 26, 2025.
Vertex Pharmaceuticals EVP and CMO Dr. Carmen Bozic sold 1,354 shares of Common Stock in an open-market transaction on May 15, 2026 at an average price of $453.45 per share. After this sale, she directly holds 24,734 shares. The trade was made under a pre-arranged Rule 10b5-1 company-approved trading plan entered into on November 20, 2025.
Vertex Pharmaceuticals submitted a Form 144 notice reporting proposed sales of Common Stock by an insider. The filing lists multiple past transactions in the prior three months and a proposed sale routed through Fidelity Brokerage Services LLC on 05/15/2026. The sales are linked to restricted stock vesting and compensation.
VRTX filing reports insider sale notices and a small employee share purchase. Mark Bunnage sold 2,437 shares on 02/17/2026 for $1,192,814.02, 1,182 shares on 02/18/2026 for $559,889.76, and 620 shares on 02/25/2026 for $301,537.00. The filing also lists a 33-share ESPP purchase on 05/14/2026.
Vertex Pharmaceuticals EVP and CMO Carmen Bozic reported an open-market sale of 6,988 shares of Common Stock at $450.00 per share. After this transaction, she directly holds 26,088 shares. The sale was carried out under a company-approved Rule 10b5-1 trading plan entered into on 11/20/2025.
Vertex Pharmaceuticals Inc. amendment to a Schedule 13G/A discloses that Capital World Investors beneficially owns 25,695,015 shares of Common Stock, equal to 10.1% of 254,034,190 shares outstanding as stated in the filing. The filing lists 25,556,582 shares as sole voting power and 25,695,015 as sole dispositive power. The amendment is signed May 13, 2026.
Vertex Pharmaceuticals Inc. ownership disclosure: Capital Research Global Investors reports beneficial ownership of 21,139,169 shares, representing 8.3% of the 254,034,190 shares believed outstanding as of the filing. The filer states sole voting power over 21,113,307 shares and sole dispositive power over 21,139,169 shares. The filing is signed by a Vice President and Senior Counsel of Capital Research and Management Company.